We claim:

1. A compound of formula (I)



(I)

wherein

each of X_1, X_2, X_3, X_4, X_5, X_6, X_7, X_8, X_9 and X_{10} is C, CH, or N; provided that each of rings A or B has no more than 2 nitrogen atoms;

E is O or NH;

v is 1, 2, or 3;

R^1 and R^2 are independently selected from hydrogen, C_1-C_8 alkyl, C_2-C_8 alkenyl, C_2-C_8 alkynyl, aryl, C_3-C_8 cycloalkyl, -C_1-C_{10} alkylaryl, heterocyclyl, -C_1-C_{10} alkylheterocyclic, -arylheterocyclyl, -C_3-C_8 cycloalkylheterocyclyl, -C_1-C_8 alkylC(O)C_1-C_8 alkyl, aryl C(O)C_1-C_8 alkyl-, C_3-C_8 cycloalkylC(O)$(CH_2)_n$-, -C_2-C_8 alkylCH(OH)aryl, -C_2-C_8alkylCH(OH)cycloalkyl, -C_2-C_8 alkylCH(OH)heterocyclyl C_2-C_8 alkylCH(OH)aryl, -C_1-C_8 alkylC(O)heterocyclic, -C_1-C_8 alkylC(O)aryl, aryloxyC_1-C_8 alkyl-, benzhydryl, fused bicyclic, C_1-C_8 alkylfused bicyclic, phenylC(O)-, phenylC(O) C_1-C_8 alkyl-, C_1-C_8 alkoxyC_1-C_8 alkyl-,-CO(O)C_1-C_8alkyl, -SO_2C_1-C_8alkyl, -SO_2C_1-C_{10} alkylaryl, -SO_2C_1-C_8 alkylheterocyclic, -C_1-C_8 alkylcycloalkyl, -$(CH_2)_nC(O)OR^8$, -$(CH_2)_nC(O)R^8$, -$(CH_2)_mC(O)NR^8R^8$, and -$(CH_2)_mNSO_2R^8$; wherein each of the alkyl, alkenyl, cycloalkyl, heterocyclic, and aryl groups are optionally substituted with one to five groups independently selected from halo, C_1-C_8 haloalkyl, C_1-C_8 thioalkyl, C_1-C_8 alkyl, C_2-C_8 alkenyl, aryl, -C_1-C_8 alkylaryl, -C(O)C_1-C_8 alkyl, -CO(O)C_1-C_8 alkyl, -SO_2C_1-C_8 alkyl, -SO_2C_1-C_8 alkylaryl, -SO_2C_1-C_8 alkylheterocyclic, -C_1-C_8 alkylcycloalkyl, -$(CH_2)_nC(O)OR^8$, -$(CH_2)_nC(O)R^8$; and wherein R^1 and R^2 may optionally combine with each other, or with 1, or 2 atoms adjacent to the nitrogen atom to form a 4, 5, 6, or 7-membered nitrogen-containing heterocycle which nitrogen -containing heterocycle may further have substituents selected from the group consisting of amino, C_1-C_8 alkyl, C_2-C_8

alkenyl, C_2-C_8 alkynyl, aryl, C_1-C_8 alkylaryl, -C(O)C_1-C_8 alkyl, -CO(O)C_1-C_8 alkyl, halo, oxo, C_1-C_8 haloalkyl; and wherein R^1 and R^2 may independently attach to the A ring to form a 4, 5, 6, or 7-member nitrogen-containing bicyclic heterocycle which nitrogen-containing bicyclic heterocycle may further have substituents selected from the group consisting of oxo, amino, -C_1-C_8 alkyl, -C_2-C_8 alkenyl, -C_2-C_8 alkynyl, aryl, -C_1-C_8 alkylaryl, -C(O)C_1-C_8 alkyl, -CO(O)C_1-C_8 alkyl, halo, and C_1-C_8 haloalkyl; and wherein R^1 and R^2 are not simultaneously hydrogen; and provided that when v is 2, and R^3 and $R^{3'}$ are both hydrogen or CH_3, and both A and B rings are phenyl, then the group -NR^1R^2 is not equal to –$NHCH_2$Phenyl; and further provided that when one of R^1 or R^2 is -CH_2CH_2-optionally substituted phenyl or -CH_2CH_2-optionally substituted naphthyl, or -CH_2CH_2-optionally substituted 5 or 6 member monocyclic heterocyclic aromatic, and v is 1, and both A and B rings are phenyl, then R^6 and R^7 are not simultaneously hydrogen;

R^3 and $R^{3'}$ are each independently selected from hydrogen, C_1-C_8 alkyl, C_2-C_8 alkenyl, C_2-C_8 alkynyl, aryl, -C_1-C_8 alkylcycloalkyl, and -C_1-C_8 alkylaryl;

R^4 and R^5 are each independently selected from hydrogen, C_1-C_8 alkyl, C_2-C_8 alkenyl, -C_2-C_8 alkynyl, -C_1-C_8 alkoxyalkyl, C_1-C_8 thioalkyl, halo, C_1-C_8 haloalkyl, -C_1-C_8 alkoxyhaloalkyl, aryl, -C_1-C_8 alkylaryl, -C(O)C_1-C_8 alkyl, or -C(O)OC_1-C_8 alkyl, -C_1-C_8 alkylamino, -C_1-C_8 alkylcycloalkyl, -$(CH_2)_m$C(O)C_1-C_8 alkyl, and $(CH_2)_nNR^8R^8$, wherein each R^4 or R^5 is attached to its respective ring only at carbon atoms, and wherein y is 0, 1, 2, or 3; and wherein z is 0, 1, 2, or 3;

R^6 and R^7 are each independently selected from hydrogen, C_1-C_8 alkyl, C_2-C_8 alkenyl, C_2-C_8 alkynyl, -C(O)C_1-C_8 alkyl, hydroxy, C_1-C_8 alkoxy, -SO_2C_1-C_8 alkyl, SO_2C_1-C_8 alkylaryl, -SO_2C_1-C_8 alkylheterocyclic, aryl, -C_1-C_8 alkylaryl, C_3-C_7 cycloalkyl, -C_1-C_6 alkylcycloalkyl, -$(CH_2)_n$C(O)R^8, -$(CH_2)_m$C(O)NR^8R^8, and -$(CH_2)_m$NSO_2R^8; wherein each of the alkyl, alkenyl, and aryl groups are optionally substituted with one to five groups independently selected from C_1-C_8 alkyl, C_2-C_8 alkenyl, aryl, and C_1-C_8 alkylaryl; and wherein R^6 and R^7 may independently combine with each other, and with the nitrogen atom to which they are attached or with 1, or 2 atoms adjacent to the nitrogen atom to form a 4, 5, 6, or 7-membered nitrogen containing heterocycle which nitrogen containing heterocycle may optionally have substituents selected from the group consisting of oxo, C_1-C_8 alkyl, C_2-C_8 alkenyl, C_2-C_8 alkynyl, aryl, -C_1-C_8 alkylaryl, -C(O)C_1-C_8 alkyl, -

$CO(O)C_1$-C_8 alkyl, hydroxy, C_1-C_8 alkoxy, -C_1-C_8 alkylamine, amino, halo, and haloalkyl;
R^8 is hydrogen, C_1-C_8 alkyl, C_2-C_8 alkenyl, C_1-C_8 alkylaryl, -$C(O)C_1$-C_8 alkyl, or -$C(O)OC_1$-C_8 alkyl; and wherein n is 0, 1, 2, 3 or 4 and m is 1, 2, or 3;
or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixture of diastereomers thereof.

2. The compound according to claim 1 wherein the A-ring is selected from the group consisting of phenyl, pyridine, pyrimidine, pyrazine, and pyridazine.

3. A compound according to Claim 1 wherein the B-ring is selected from the group consisting of phenyl, pyridine, pyrimidine, pyrazine, and pyridazine.

4. A compound according to Claim 1 wherein the A-ring is phenyl and the B ring is pyridinyl.

5. A compound according to Claim 1 wherein the A ring is phenyl and the B ring is pyrazinyl.

6. A compound according to Claim 1 wherein the A-ring is pyridinyl and the B-ring is phenyl.

7. A compound according to Claim 1 wherein both rings A and B are pyridinyl.

8. A compound according to Claim 1 wherein both rings A and B are phenyl.

9. A compound according to any one of Claims 1 to 8 wherein E is an oxygen atom.

10. A compound according to Claim 1 wherein y is 0, 1, or 2, and R^4 is independently selected from the group consisting of hydrogen, fluoro, chloro, bromo.

methoxy, ethoxy, methyl, ethyl, isopropyl, trifluoromethyl, trifluoromethoxy, phenyl, and benzyl.

11. A compound according to Claim 1 wherein z is 0, 1, or 2, and R^5 is independently selected from the group consisting of hydrogen, fluoro, chloro, bromo, methoxy, ethoxy, methyl, ethyl, isopropyl, trifluoromethyl, trifluoromethoxy, phenyl, and benzyl.

12. A compound according to Claim 1 wherein R^1 and R^2 are each independently selected from the group consisting of hydrogen, methyl, ethyl, propyl, isopropyl, phenyl,



and wherein n is 1, 2, or 3.

13. The compound according to any one of Claims 1 to 12 wherein R^6 and R^7 are each independently selected from the group consisting of hydrogen, methyl, ethyl, propyl, isopropyl, phenyl, provided that when one of R^1 or R^2 is -CH_2CH_2-optionally substituted phenyl or -CH_2CH_2-optionally substituted naphthyl, or -CH_2CH_2-optionally substituted 5 or 6 member monocyclic heterocyclic aromatic, and v is 1, and the B ring is phenyl, then R^6 and R^7 are not simultaneously hydrogen.

14. A compound according to any one of Claims 1 to 12 wherein E is an oxygen atom, R^6 and R^7 are each hydrogen provided that R^1 and R^2 are not simultaneously hydrogen and further provided that when one of R^1 or R^2 is $-CH_2CH_2-$optionally substituted phenyl or $-CH_2CH_2-$optionally substituted naphthyl, or $-CH_2CH_2-$optionally substituted 5 or 6 member monocyclic heterocyclic aromatic, and v is 1, the B ring is not phenyl.

15. A compound according to any one of Claims 1 to 12 wherein v is 1 or 2.

16. A compound according to any one of Claims 1 to 12 wherein v is 1.

17. A compound according to any one of Claims 1 to 12 wherein vis 2, m is 1, n is 1, y is 0 or 1 and z is 0 or 1.

18. A compound selected from the group consisting of:

6-{4-[(3-Methyl-butylamino)-methyl]-phenoxy}-nicotinamide



,

5-{2-Fluoro-4-[(3-methyl-butylamino)-methyl]-phenoxy}-pyrazine-2-carboxamide



5-(2-Methoxy-4-pentylaminomethyl-phenoxy)-pyrazine-2-carboxamide



,

6-(2-Fluoro-4-{[2-(tetrahydro-pyran-4-yl)-ethylamino]-methyl}-phenoxy)-nicotinamide



,

6-(2,3-Difluoro-4-pentylaminomethyl-phenoxy)-nicotinamide



,

5-(4-{[2-(4-Fluoro-phenyl)-ethylamino]-methyl}-2-methoxy-phenoxy)-pyrazine-2-carboxamide



,

5-{4-[(4,4-Dimethyl-pentylamino)-methyl]-2-methoxy-phenoxy}-pyrazine-2-carboxamide



,

5-(2-Methoxy-4-{[2-(tetrahydro-pyran-4-yl)-ethylamino]-methyl}-phenoxy)-pyrazine-2-carboxamide



,

5-{4-[(3,3-Dimethyl-butylamino)-methyl]-2-fluoro-phenoxy}-pyrazine-2-carboxamide



.

5-(2-Fluoro-4-{[2-(tetrahydro-pyran-4-yl)-ethylamino]-methyl}-phenoxy)-pyrazine-2-carboxamide



,

6-{2-Methyl-4-[(3-methyl-butylamino)-methyl]-phenoxy}-nicotinamide; methanesulfonic acid salt



,

5-(2-Methyl-4-{[2-(tetrahydro-pyran-4-yl)-ethylamino]-methyl}-phenoxy)-pyrazine-2-carboxamide



,

6-{4-[(3,3-Dimethyl-butylamino)-methyl]-2-fluoro-6-methoxy-phenoxy}-nicotinamide



,

5-(2-Fluoro-4-pentylaminomethyl-phenoxy)-pyrazine-2-carboxamide



,

3-Chloro-4-{4-[(3,3-dimethyl-butylamino)-methyl]-phenoxy}-benzamide



,

6-(4-{[2-(Tetrahydro-pyran-4-yl)-ethylamino]-methyl}-phenoxy)-nicotinamide



,

6-{4-[2-(3,3-Dimethyl-butylamino)-ethyl]-2,6-difluoro-phenoxy}-nicotinamide



,

6-{2-Chloro-4-[(3-methyl-butylamino)-methyl]-phenoxy}-nicotinamide



,

3,5-Difluoro-4-{4-[(3-methyl-butylamino)-methyl]-phenoxy}-benzamide



,

6-{2,3,6-Trifluoro-4-[(3-methyl-butylamino)-methyl]-phenoxy}-nicotinamide



,

6-{2,6-Difluoro-4-[(3-methyl-butylamino)-methyl]-phenoxy}-nicotinamide



,

3-Fluoro-4-{4-[(3-methyl-butylamino)-methyl]-phenoxy}-benzamide



,

and a pharmaceutically acceptable salt, or solvate thereof.

19. The compound 6-{4-[(3-Methyl-butylamino)-methyl]-phenoxy}-nicotinamide



or a pharmaceutically acceptable salt, or solvate thereof.

20. The hydrochloric acid salt of the compound 6-{4-[(3-Methyl-butylamino)-methyl]-phenoxy}-nicotinamide



21. The compound 5-(4-{[2-(4-Fluoro-phenyl)-ethylamino]-methyl}-2-methoxy-phenoxy)-pyrazine-2-carboxamide



or a pharmaceutically acceptable salt, or solvate thereof.

22. The compound 5-(2-Methoxy-4-pentylaminomethyl-phenoxy)-pyrazine-2-carboxylic acid amide



or a pharmaceutically acceptable salt, or solvate thereof.

23. The compound 5-(2-Methoxy-4-{[2-(tetrahydro-pyran-4-yl)-ethylamino]-methyl}-phenoxy)-pyrazine-2-carboxamide



or a pharmaceutically acceptable salt, or solvate thereof.

24. The compound 6-(2-Fluoro-4-{[2-(tetrahydro-pyran-4-yl)-ethylamino]-methyl}-phenoxy)-nicotinamide; methanesulfonic acid salt



25. A compound according to any one of Claims 1 to 18 wherein the pharmaceutically acceptable salt is the hydrochloric acid salt, the methanesulfonic acid salt, hydrobromide salt, the bisulfate salt or tartaric acid salt.

26. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of Claims 1 to 24 in association with a carrier, diluent and/or excipient.

27. A method for blocking a mu, kappa, delta or receptor combination (heterodimer) thereof in mammals comprising administering to a mammal requiring blocking of a mu, kappa, delta or receptor combination (heterodimer) thereof, a receptor blocking dose of a compound according to any one of Claims 1 to 24, or a pharmaceutically acceptable salt, enantiomer, racemate, mixture of diastereomers, or solvate thereof.

28. A method of treating or preventing obesity and Related Diseases comprising administering a therapeutically effective amount of a compound of formula II wherein formula II is represented by the structure



(II)

wherein

each of $X_{1'}$, $X_{2'}$, $X_{3'}$, $X_{4'}$, $X_{5'}$, $X_{6'}$, $X_{7'}$, $X_{8'}$, $X_{9'}$ and $X_{10'}$ is C, CH, or N; provided that each of rings A' or B' has no more than 2 nitrogen atoms;

E' is O or NH;

v is 0, 1, 2 or 3;

$R^{1'}$ and $R^{2'}$ are independently selected from hydrogen, C_1-C_8 alkyl, C_2-C_8 alkenyl, C_2-C_8 alkynyl, aryl, C_3-C_8 cycloalkyl, -C_1-C_{10} alkylaryl, heterocyclyl, -C_1-C_{10} alkylheterocyclic, -arylheterocyclyl, -C_3-C_8 cycloalkylheterocyclyl, -C_1-C_8 alkylC(O)C_1-C_8 alkyl, aryl C(O)C_1-C_8 alkyl-, C_3-C_8 cycloalkylC(O)$(CH_2)_n$-, -C_2-C_8 alkylCH(OH)aryl, -C_2-C_8alkylCH(OH)cycloalkyl, -C_2-C_8 alkylCH(OH)heterocyclyl C_2-C_8 alkylCH(OH)aryl, -C_1-C_8 alkylC(O)heterocyclic, -C_1-C_8 alkylC(O)aryl, aryloxyC_1-C_8 alkyl-, benzhydryl, fused bicyclic, C_1-C_8 alkylfused bicyclic, phenylC(O)-, phenylC(O) C_1-C_8 alkyl-, C_1-C_8 alkoxyC_1-C_8 alkyl-,-CO(O)C_1-C_8alkyl, -SO_2C_1-C_8alkyl, -SO_2C_1-C_{10} alkylaryl, -SO_2C_1-C_8 alkylheterocyclic, -C_1-C_8 alkylcycloalkyl, -$(CH_2)_nC(O)OR^8$, -$(CH_2)_nC(O)R^8$, -$(CH_2)_mC(O)NR^8R^8$, and -$(CH_2)_mNSO_2R^8$; wherein each of the alkyl, alkenyl, cycloalkyl, heterocyclic, and aryl groups are optionally substituted with one to five groups independently selected from halo, C_1-C_8 haloalkyl, C_1-C_8 thioalkyl, C_1-C_8 alkyl, C_2-C_8 alkenyl, aryl, -C_1-C_8 alkylaryl, -C(O)C_1-C_8 alkyl, -CO(O)C_1-C_8 alkyl, -SO_2C_1-C_8 alkyl, -SO_2C_1-C_8 alkylaryl, -SO_2C_1-C_8 alkylheterocyclic, -C_1-C_8 alkylcycloalkyl, -$(CH_2)_nC(O)OR^8$, -$(CH_2)_nC(O)R^8$; and wherein $R^{1'}$ and $R^{2'}$ may optionally combine with each other, or with 1, or 2 atoms adjacent to the nitrogen atom to form a 4, 5, 6, or 7-membered nitrogen-containing heterocycle which nitrogen -containing heterocycle may further have substituents selected from the group consisting of amino, C_1-C_8 alkyl, C_2-C_8

alkenyl, C_2-C_8 alkynyl, aryl, C_1-C_8 alkylaryl, -C(O)C_1-C_8 alkyl, -CO(O)C_1-C_8 alkyl, halo, oxo, C_1-C_8 haloalkyl; and wherein $R^{1'}$ and $R^{2'}$ may independently attach to the A' ring to form a 4, 5, 6, or 7-member nitrogen-containing bicyclic heterocycle which nitrogen-containing bicyclic heterocycle may further have substituents selected from the group consisting of oxo, amino, -C_1-C_8 alkyl, -C_2-C_8 alkenyl, -C_2-C_8 alkynyl, aryl, -C_1-C_8 alkylaryl, -C(O)C_1-C_8 alkyl, -CO(O)C_1-C_8 alkyl, halo, and C_1-C_8 haloalkyl; provided that $R^{1'}$ and $R^{2'}$ are not simultaneously hydrogen; and provided that when v is 2, and R^{3a} and R^{3b} are both hydrogen or CH_3, and both A' and B' rings are phenyl, then the group -$NR^{1'}R^{2'}$ is not equal to –$NHCH_2$Phenyl; and further provided that when one of $R^{1'}$ or $R^{2'}$ is -CH_2CH_2-optionally substituted phenyl or -CH_2CH_2-optionally substituted naphthyl, or -CH_2CH_2-optionally substituted 5 or 6 member monocyclic heterocyclic aromatic, and v is 1, and both A' and B' rings are phenyl, then $R^{6'}$ and $R^{7'}$ are not simultaneously hydrogen;

R^{3a} and R^{3b} are each independently selected from hydrogen, C_1-C_8 alkyl, C_2-C_8 alkenyl, C_2-C_8 alkynyl, aryl, -C_1-C_8 alkylcycloalkyl, aryl, and -C_1-C_8 alkylaryl;

$R^{4'}$ and $R^{5'}$ are each independently selected from hydrogen, C_1-C_8 alkyl, C_2-C_8 alkenyl, -C_2-C_8 alkynyl, -C_1-C_8 alkoxyalkyl, C_1-C_8 thioalkyl, halo, C_1-C_8 haloalkyl, -C_1-C_8 alkoxyhaloalkyl, aryl, -C_1-C_8 alkylaryl, -C(O)C_1-C_8 alkyl, or -C(O)OC_1-C_8 alkyl, -C_1-C_8 alkylamino, -C_1-C_8 alkylcycloalkyl, -$(CH_2)_m$C(O)C_1-C_8 alkyl, and -$(CH_2)_n$$NR^8R^8$, wherein each $R^{4'}$ and $R^{5'}$ is attached to its respective ring only at carbon atoms, and wherein y is 0, 1, 2, or 3; and wherein z is 0, 1, 2, or 3;

$R^{6'}$ and $R^{7'}$ are each independently selected from hydrogen, C_1-C_8 alkyl, C_2-C_8 alkenyl, C_2-C_8 alkynyl, -C(O)C_1-C_8 alkyl, hydroxy, C_1-C_8 alkoxy, -SO_2C_1-C_8 alkyl, SO_2C_1-C_8 alkylaryl, -SO_2C_1-C_8 alkylheterocyclic, aryl, -C_1-C_8 alkylaryl, C_3-C_7 cycloalkyl, -C_1-C_6 alkylcycloalkyl, -$(CH_2)_n$C(O)R^8, -$(CH_2)_m$C(O)NR^8R^8, and -$(CH_2)_m$$NSO_2R^8$; wherein each of the alkyl, alkenyl, and aryl groups are optionally substituted with one to five groups independently selected from C_1-C_8 alkyl, C_2-C_8 alkenyl, aryl, and C_1-C_8 alkylaryl; and wherein $R^{6'}$ and $R^{7'}$ may independently combine together, and with the nitrogen atom to which they are attached or with 1, or 2 atoms adjacent to the nitrogen atom to form a 4, 5, 6, or 7-membered nitrogen containing heterocycle which nitrogen containing heterocycle may further have substituents selected from the group consisting of C_1-C_8 alkyl, C_2-C_8

alkenyl, C_2-C_8 alkynyl, phenyl, -C_1-C_8 alkylaryl, -C(O)C_1-C_8 alkyl, -CO(O)C_1-C_8 alkyl, hydroxy, -C_1-C_8 alkoxy, halo, and haloalkyl;
R^8 is hydrogen, C_1-C_8 alkyl, C_2-C_8 alkenyl, C_1-C_8 alkylaryl, -C(O)C_1-C_8 alkyl, or -C(O)OC_1-C_8 alkyl; wherein n is 0, 1, 2, 3 or 4 and wherein m is 1, 2 or 3;
or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomers or mixtures thereof.

29. A method according to Claim 28 wherein the Related Diseases is selected from the group consisting of diabetes, diabetic complications, diabetic retinopathy, atherosclerosis, hyperlipidemia, hypertriglycemia, hyperglycemia, and hyperlipoproteinemia.

30. A method of treating and/or preventing diseases related to obesity including irritable bowel syndrome, nausea, vomiting, obesity-related depression, obesity–related anxiety, smoking and alcohol addiction, sexual dysfunction, substance abuse, drug overdose, addictive behavior disorders, compulsive behaviors and stroke, comprising administering a therapeutically effective amount of a compound of formula I or II.

31. Use of a compound of formula I according to any one of Claims 1 to 24 or a compound of formula II according to Claim 28 in the manufacture of a medicament for the treatment and/or amelioration of the symptoms associated with obesity and Related Diseases.

32. A method of treating and/or preventing obesity and Related Diseases comprising administering a therapeutically effective amount of a compound of formula I or II to a patient in need thereof.

33. A method of suppressing appetite in a patient in need thereof, comprising administering a therapeutically effective amount of a compound of formula I or II.

34. A method of effecting weight loss in an obese patient comprising administering an effective amount of a compound of formula I or formula II or pharmaceutically acceptable salt, solvate, racemate or enantiomer thereof.

35. Use of a compound according to Claim 18 for the treatment of obesity comprising administering an effective dose of said compound to a person in need thereof.

36. Use of a compound according to Claim 18 for the treatment of weight loss comprising administering an effective dose of said compound to a person in need thereof.

37. Use of a compound according to Claim 19 or 20 or 21 or 22 or 23 or 24 for the treatment of obesity comprising administering an effective dose of said compound to a person in need thereof.

38. A pharmaceutical composition for the treatment and/or amelioration of the symptoms associated with obesity and Related Diseases, containing as an active ingredient a compound of formula I according to any one of Claims 1 to 24 or a compound of formula II according to Claim 28.